While enzalutamide combinations were synergistic and resulted in greater prostate cancer cell death, it is still important to note that docetaxel combinations were synergistic to additive in some of our models, citing the importance of using docetaxel in the clinic in some cases, especially when AR-Vs are not expressed. This evidence concerns the gene AR and prostate carcinoma.